Compare ALTI & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALTI | LAB |
|---|---|---|
| Founded | 2020 | 1999 |
| Country | United States | United States |
| Employees | 490 | N/A |
| Industry | Investment Managers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.2M | 365.2M |
| IPO Year | 2021 | 2008 |
| Metric | ALTI | LAB |
|---|---|---|
| Price | $3.86 | $1.00 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.35 |
| AVG Volume (30 Days) | 147.7K | ★ 3.2M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.11 | ★ 61.54 |
| EPS | N/A | ★ 0.33 |
| Revenue | ★ $254,956,000.00 | $101,937,000.00 |
| Revenue This Year | $18.06 | N/A |
| Revenue Next Year | $10.71 | $2.63 |
| P/E Ratio | ★ N/A | $3.05 |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $2.96 | $0.87 |
| 52 Week High | $5.45 | $1.72 |
| Indicator | ALTI | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 56.06 | 58.86 |
| Support Level | $3.73 | $0.90 |
| Resistance Level | $3.96 | $1.02 |
| Average True Range (ATR) | 0.21 | 0.05 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 82.85 | 75.05 |
AlTi Global Inc is a wealth and investment partner to families, foundations, and institutions, helping clients activate capital, bring structure to complexity, and plan across borders and generations. The company combines the breadth of an international firm with the service offering of a family office to deliver solutions for wealth and capital. It provides services including discretionary and non-discretionary investment advisory, estate and wealth planning, trust and fiduciary, governance, philanthropy, and family office services, along with access to alternative investment opportunities. The company generates revenue from management, advisory, trustee, or administration fees, performance or incentive fees, distributions from investments, and other income or fees.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.